化浊通脉方治疗痰瘀痹阻型冠心病临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R541.4

基金项目:

海宁市科技计划项目(2021109)


Clinical Study on Huazhuo Tongmai Prescription in the Treatment of Coronary Heart Disease of Phlegm-Stasis Obstruction Type
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察化浊通脉方治疗痰瘀痹阻型冠心病的疗效。方法:选取2021年9月—2023年8月海宁 市中医院心内科收治的120例痰瘀痹阻型冠心病患者,按随机数字表法分为观察组及对照组各60例。对照组予 以现代医学常规治疗,观察组在对照组基础上给予化浊通脉方治疗。观察2组不良反应发生情况,比较2组治 疗前后中医证候积分、血脂(血清总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、甘油三酯)、血 糖(空腹血糖、餐后2 h血糖、糖化血红蛋白) 的变化。结果:治疗后,观察组中医证候积分较治疗前下降, 且低于对照组,差异均有统计学意义(P<0.05);对照组治疗前后比较,差异无统计学意义(P>0.05)。治疗 后,观察组血清总胆固醇、低密度脂蛋白胆固醇均较治疗前下降,且均低于对照组,差异均有统计学意 义(P<0.05);2组甘油三酯、高密度脂蛋白胆固醇治疗前后比较、组间比较,差异均无统计学意义(P> 0.05)。治疗后,观察组空腹血糖及餐后2 h血糖均较治疗前下降(P<0.05),且空腹血糖低于对照组(P< 0.05)。2组糖化血红蛋白水平治疗前后比较、组间比较,差异均无统计学意义(P>0.05)。在治疗过程中,观 察组1例出现腹泻,经治疗后症状消失。结论:化浊通脉方治疗痰瘀痹阻型冠心病疗效较好,有助于控制血 脂、血糖。

    Abstract:

    Abstract:Objective:To observe the effect of Huazhuo Tongmai Prescription in the treatment of coronary heart disease (CHD) of phlegm-stasis obstruction type. Methods: A total of 120 patients with CHD of phlegm-stasis obstruction type admitted to the Department of Cardiology, Haining Hospital of Chinese Medicine from September 2021 to August 2023 were selected. They were divided into the observation group and the control group by the random number table method,with 60 cases in each group. The control group was given conventional modern medical treatment, while the observation group was given Huazhuo Tongmai Prescription on the basis of the control group's treatment. The incidence of adverse reactions was observed. The changes in traditional Chinese medicine (TCM) syndrome scores, blood lipids (serum total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides), and blood glucose (fasting blood glucose, 2-hour postprandial blood glucose, glycated hemoglobin) before and after treatment were compared between the two groups. Results:After treatment,the TCM syndrome scores in the observation group were decreased when compared with those before treatment and were lower than those in the control group,differences being significant (P<0.05);there was no statistically significant difference in the control group before and after treatment or between the two groups (P>0.05). After treatment,the serum total cholesterol and low-density lipoprotein cholesterol in the observation group were decreased when compared with those before treatment and were lower than those in the control group, differences being significant (P<0.05); there was no significant difference in triglycerides and high-density lipoprotein cholesterol between the two groups before and after treatment or between the two groups (P>0.05) . After treatment,the fasting blood glucose and 2-hour postprandial blood glucose in the observation group were decreased when compared with those before treatment (P<0.05),and the fasting blood glucose was lower than that in the control group (P<0.05) . There was no significant difference in glycated hemoglobin level between the two groups before and after treatment or between the two groups (P>0.05). During the treatment,one patient in the observation group had diarrhea,and the symptoms disappeared after treatment. Conclusion:Huazhuo Tongmai Prescription has a good effect in the treatment of CHD of phlegm-stasis obstruction type, and is helpful for controlling blood lipids and blood glucose.

    参考文献
    相似文献
    引证文献
引用本文

孙迪,叶林斌,乔红元,陆敏锋,汪小波.化浊通脉方治疗痰瘀痹阻型冠心病临床研究[J].新中医,2026,58(1):49-53

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2026-01-12
  • 出版日期:
文章二维码